

Sandoz, A Novartis Division



Sustainability of Antibiotics – Public Meeting, Presidential Advisory Council on Combating Antibiotic-resistant Bacteria

Harshika Sarbajna Global Head, Anti-infectives, Sandoz International GmbH January 2019




Most bacterial infections are still treatable with existing antibiotics...

Lets keep it that way!

#keep-antibiotics-working



One cause of AMR we don't talk enough about – poor access to right antibiotics!



SANDOZ A Novartis Division

Reasons behind poor access go beyond customer affordability in developed markets



Issues with market attractiveness – pricing mechanisms, tender practices, cost containment measures



Fragile supply chain with too few API or other suppliers, surge in demand or limited capacities




Regulatory time lag and often differing national requirements across countries **QUALITY**

Unanticipated issues related to quality




Fix for the long term - Need more carrots than sticks



- Hold industry accountable for quality & reliability not the lowest price
- Promote a healthy market price by value instead of lowest cost
- Publish essential Antibiotics list
- Simplify marketing authorization/revision process
- Streamline supply alternatives, including alternative therapies or international products



Collaboration is key!





Thank You!

